Amlodipine And Atorvastatin Tablet, Film Coated
Product Images NDC 72162-2090

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine And Atorvastatin (NDC 72162-2090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Amlodipine Besylate And Atorvastatin Calcium 02)

A line graph comparing event rates over 24 months between Amlodipine and Placebo groups. The x-axis represents time in months, and the y-axis represents event rate. The graph shows two curves labeled 'Amlodipine' and 'Placebo,' with accompanying statistical data including a p-value of 0.003, hazard ratio of 0.691, and 95% confidence interval of 0.54 to 0.88.*

FDA Label Image

Figure 2 (Amlodipine Besylate And Atorvastatin Calcium 03)

A forest plot displaying hazard ratios with 95% confidence intervals comparing Amlodipine and placebo across various patient subgroups. The graph includes overall patients, age groups, gender, baseline sitting systolic blood pressure, vessel disease status, vessel stenosis, and PCI stent strata, with markers showing favorability towards Amlodipine or placebo.*

FDA Label Image

Figure 3 (Amlodipine Besylate And Atorvastatin Calcium 04)

A line graph showing cumulative incidence (%) over time in years, comparing Atorvastatin (solid line) and Placebo (dashed line) groups. The graph includes a hazard ratio (HR = 0.64) with confidence interval and p-value, indicating statistical data visualization.*

FDA Label Image

Figure 4 (Amlodipine Besylate And Atorvastatin Calcium 05)

A line graph showing cumulative hazard percentages over time to first primary endpoint during four years of follow-up. Two curves compare Placebo (dashed line) and Atorvastatin (solid line), with Atorvastatin showing a lower cumulative hazard. The graph includes a hazard ratio (HR 0.63) with confidence interval (0.48-0.83) and p-value (0.001).*

FDA Label Image

Figure 5 (Amlodipine Besylate And Atorvastatin Calcium 06)

A line graph comparing the percentage of subjects experiencing a major cardiovascular event over time (years) for Atorvastatin 10 mg and 80 mg doses. The x-axis shows time to first major cardiovascular endpoint in years, ranging from 0 to 5 years, and the y-axis shows the percentage of subjects experiencing the event, up to 0.2 (20%). Two lines depict the event rates for the 10 mg dose (dashed line) and 80 mg dose (solid line). The graph includes a hazard ratio (HR) of 0.78 with confidence interval and p-value below the plot area.*

FDA Label Image

Amlodipine (Amlodipine)

Chemical structure diagram showing molecular components, including a chlorophenyl group, ester, sulfonic acid, and amine functional groups. This corresponds to the active ingredients Amlodipine and Atorvastatin as indicated by product data.*

FDA Label Image

Atorvastatin-glycol-solvate (Atorvastatin Glycol Solvate)

Chemical structure diagram showing the molecular arrangement of the active ingredients in Amlodipine and Atorvastatin tablets, including calcium and other components, consistent with the combined pharmaceutical formulation.*

FDA Label Image

Label (Lbl721622090)

Label for Amlodipine and Atorvastatin Tablets USP, 10 mg/20 mg film-coated tablets. The label shows the drug name, strength, and that the package contains 30 tablets. It includes storage instructions, a bar code, and mentions the labeler Bryant Ranch Prepack, Inc., and manufacturer Apotex Inc. The label is for prescription use only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.